Nurix Therapeutics: Christine Ring sells 5,786 shares

Q: How many NRIX shares did Christine Ring sell, and at what price?

Christine Ring sold 5,786 common shares on October 2, 2026, at a weighted average price of $23.1851 per share. The reported sale prices ranged from $22.84 to $23.65, and the sale was effected under a previously adopted Rule 10b5-1 trading plan.

The options vest monthly through February 13, 2027, subject to Christine Ring providing service to Nurix Therapeutics on each vesting date.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring exercised 5,786 stock options on October 2, 2026, at an exercise price of $8.72 per share, acquiring 5,786 common shares. She sold 5,786 common shares that day at a weighted average price of $23.1851 per share; the sale was made under a previously adopted Rule 10b5-1 trading plan. Reported option holdings after the exercise were 111,251.

Insider Trade Summary 10b5-1

Exercise and Sale: 5,786 shares ($84K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Ring Christine

Role Chief Legal Officer

Sold 5,786 shs ($134K)

Approx. gross sale proceeds $134K

Approx. exercise cost $50K

Approx. pre-tax spread $84K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy) ^{F1, F3}	5,786	$0.00	$0.00
Exercise	Common Stock ^F1	5,786	$8.72	$50K
Sale	Common Stock ^{F1, F2}	5,786	$23.1851	$134K

Holdings After Transaction: Employee Stock Option (right to buy) — 111,251 contracts (Direct); Common Stock — 9,110 shares (Direct)

Footnotes (3)

F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2. Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Stock options exercised: 5,786 options Exercise price: $8.72 per share Common shares acquired through exercise: 5,786 shares +4 more

7 metrics

Stock options exercised 5,786 options October 2, 2026

Exercise price $8.72 per share Options exercised October 2, 2026

Common shares acquired through exercise 5,786 shares October 2, 2026

Common shares sold 5,786 shares October 2, 2026

Weighted average sale price $23.1851 per share October 2, 2026

Reported sale price range $22.84-$23.65 per share Shares sold October 2, 2026

Reported option holdings after exercise 111,251 options Following the October 2, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, vesting

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan previously adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price"

vesting financial

"vests as to 1/36 of the total shares monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NRIX shares did Christine Ring sell, and at what price?

Christine Ring sold 5,786 common shares on October 2, 2026, at a weighted average price of $23.1851 per share. The reported sale prices ranged from $22.84 to $23.65, and the sale was effected under a previously adopted Rule 10b5-1 trading plan.

What was the vesting schedule for Christine Ring's NRIX options?

The stock option vests as to 1/36 of the total shares monthly, beginning March 13, 2024, until fully vested on February 13, 2027, subject to Christine Ring's provision of service to Nurix Therapeutics on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/02/2026 - 05:21 PM Accepted by SEC EDGAR 10/02/2026 - 05:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last)

(First)

(Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/02/2026		M⁽¹⁾		5,786	A	$8.72	14,896	D
Common Stock	10/02/2026		S⁽¹⁾		5,786	D	$23.1851⁽²⁾	9,110	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$8.72	10/02/2026		M⁽¹⁾			5,786	⁽³⁾	02/12/2034	Common Stock	5,786	$0	111,251	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR